Addendum
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Addendum to Project A26-09
Report documents
-
Addendum
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Addendum to Project A26-09
Dossier assessment
Indication:
Treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1, aged 1 to < 3 years
Result of dossier assessment:
Unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-76
- Commission
- Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-76_en
Connected Projects
-
Dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed